Diane Weiser | Senior Vice President of Corporate Communications & Investor Relations |
Robert Blum | President & Chief Executive Officer |
Fady Malik | Executive Vice President, Research & Development |
Stuart Kupfer | Senior Vice President & Chief Medical Officer |
Andrew Callos | Executive Vice President & Chief Commercial Officer |
Robert Wong | Vice President & Chief Accounting Officer |
Ching Jaw | Senior Vice President & Chief Financial Officer |
Srikripa Devarakonda | Truist |
Salim Syed | Mizuho |
Tessa Romero | JPMorgan |
Charles Duncan | Cantor Fitzgerald |
Yasmeen Rahimi | Piper Sandler |
Akash Tewari | Jefferies |
Jeff Hung | Morgan Stanley |
Jason Zemansky | Bank of America |
Jason Butler | JMP Securities |
Rohit Bhasin | Needham & Co. |
Omari Baruti | Goldman Sachs |
Ash Verma | UBS |
Dane Leone | Raymond James |
Justin Kim | Oppenheimer |
Good afternoon and welcome ladies and gentlemen to Cytokinetics' First Quarter 2023 Conference Call. At this time, I would like to inform you that this call is being recorded and that all participants are in a listen-only mode. At the company's request, we will open the call for question-and-answer after the presentation.
We will allow for one question per participant.
I will now turn the call over to Diane Weiser, Cytokinetic's Senior Vice President of Corporate Communications and Investor Relations.